Organization | Changchun Institute of Biological Products Co., Ltd.

Changchun Institute of Biological Products Co., Ltd. Report issue

For profit Phase 1 Phase 4

Founded: Changchun China (1985)

Status: Defunct (2019)

Organization Overview

First Clinical Trial

2015

NCT02603055

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Changchun Institute of Biological Products Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (6)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (3 trials)

covax-19 (2 trials)

ev71 vaccine (1 trial)

hepatitis a (live) vaccine (1 trial)

inactivated influenza vaccine (4 trials)

inactivated rabies vaccine (Imovax) (1 trial)

Drugs in Phase 1 Trials (2)

hepatitis e vaccine (1 trial)

split virion influenza vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Enterovirus Infections (Phase 4)

Hepatitis (Phase 1)

Hepatitis A (Phase 4)

Hepatitis E (Phase 1)

Influenza, Human (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 8